Alveolar rhabdomyosarcoma (ARMS) is an aggressive childhood cancer of striated muscle characterized by the presence of the PAX3-FOXO1A or PAX7-FOXO1A chimeric oncogenic transcription factor. Identification of their targets is essential for understanding ARMS pathogenesis. To this aim, we analyzed transcriptomic data from rhabdomyosarcoma samples and found that P-cadherin expression is correlated with PAX3/7-FOXO1A presence. We then show that expression of a PAX3 dominant negative variant inhibits P-cadherin expression in ARMS cells. Using mouse models carrying modified Pax3 alleles, we demonstrate that P-cadherin is expressed in the dermomyotome and lies genetically downstream from the myogenic factor Pax3. Moreover, in vitro gel shift analysis and chromatin immunoprecipitation indicate that the P-cadherin gene is a direct transcriptional target for PAX3/7-FOXO1A. Finally, P-cadherin expression in normal myoblasts inhibits myogenesis and induces myoblast transformation, migration and invasion. Conversely, P-cadherin downregulation by small hairpin RNA decreases the transformation, migration and invasive potential of ARMS cells. P-cadherin also favors cadherin switching, which is a hallmark of metastatic progression, by controlling N-and M-cadherin expression and/or localization. Our findings demonstrate that P-cadherin is a direct PAX3-FOXO1A transcriptional target involved in ARMS aggressiveness. Therefore, P-cadherin emerges as a new and attractive target for therapeutic intervention in ARMS.
INTRODUCTION
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma and 450% of all soft tissue sarcomas in children are RMS. 1 As RMS show some characteristics of skeletal muscle, they are thought to be the result of deregulation of the growth and differentiation of skeletal muscle precursor cells. RMS are classified into two major subtypes: embryonal (ERMS) and alveolar rhabdomyosarcoma (ARMS). Whereas no consistent and unique genetic alterations have been identified in ERMS, ARMS are characterized by a reciprocal translocation that results in PAX3-FOXO1A or PAX7-FOXO1A fusion proteins, consisting of the NH2-terminal PAX3/PAX7 DNA-binding domain and the COOHterminus of the transactivation domain of FOXO1A, a member of the forkhead/HNF-3 transcription factor family. 2 A translocation that generates a fusion protein composed of PAX3 and the nuclear receptor coactivator NCOA1 has also been described. 3 These fusion proteins are more potent transcriptional activators than wild-type PAX3/7 proteins, suggesting that specific PAX3/7 target genes may be deregulated and thereby involved in ARMS development/aggressiveness. 4, 5 Indeed, conditional activation of PAX3-FOXO1A in skeletal muscle of mice in which the Ink4a/Arf or p53 pathways are inactivated leads to the development of murine ARMS. 6 Moreover, ARMS have the worse prognosis amongst RMS and the PAX3-FOXO1A translocation is associated with increased treatment failure and mortality rate. 7 Thus, the identification of direct PAX3/7-FOXO1A target genes is essential for improving therapeutic strategies and also will help delineating the signaling pathways involved in the progression of ARMS to the metastatic stage when o10% of patients will survive.
Progression toward tumor malignancy involves changes in tumor cell capabilities to adhere and communicate with neighboring cells. It is now accepted that aberrant cell adhesion is causally involved in tumor progression and metastasis rather than merely being a consequence of it. 8 Among these adhesion defects, cadherin switching has a critical role in tumor progression. 9, 10 These changes in cadherin expression not only modulate tumor cell adhesion, but also affect signal transduction and hence tumor malignancy. We previously reported the occurrence of cadherin switching (decrease in N-and M-cadherin expression concomitantly with induction of R-cadherin expression) in RMS cell lines and biopsies. 11 R-cadherin is involved in myoblast transformation; 12 however, as it is expressed in both ERMS and ARMS, it cannot explain the higher metastatic behavior of ARMS. Taking advantage of published microarray data sets from RMS samples, we identified P-cadherin as exclusively expressed in ARMS biopsies and cell lines. We show that, in mouse embryos, P-cadherin is expressed in muscle progenitor cells (MPCs) during early myogenesis and that its expression is regulated by Pax3 and PAX3/7-FOXO1A. P-cadherin expression in C2C12 myoblasts inhibits myogenesis and induces myoblast transformation, migration and invasion. Moreover, we demonstrate that P-cadherin is necessary for the migratory and invasive potential of ARMS cells. Finally, we show that P-cadherin expression favors a cadherin switch, a key step during invasion. Our study identifies P-cadherin as a new and attractive candidate for the development of treatments against ARMS.
RESULTS P-cadherin expression is correlated with PAX3-FOXO1A or PAX7-FOXO1A presence in RMS To identify cadherins involved in RMS development, we analyzed cadherin gene expression using a microarray data set from 101 RMS tumors.
13 P-cadherin expression was detected only in PAX3-FOXO1A and PAX7-FOXO1A positive ARMS (Figure 1a , left panel) but not in ERMS and in PAX3-FOXO1A or PAX7-FOXO1A negative ARMS (called ARMSfn). Analysis of P-cadherin expression in three other data sets 3, 14, 15 confirmed this finding ( Figure 1a , middle panel). P-cadherin expression was correlated with PAX3-FOXO1A, PAX7-FOXO1A and PAX3-NCOA1 presence (Figure 1a , right panel). Restricted expression of P-cadherin to fusion-positive ARMS was also observed in RMS-derived cell lines at mRNA and protein levels, with Rh28, Rh4, Rh5 and SJRh30 ARMS cell lines expressing the highest levels ( Figure 1b ). P-cadherin was never detected in control human myoblasts (LHCN-M2) and ERMS cell lines. Immunocytochemistry analysis confirmed the expression of P-cadherin in ARMS cell lines and revealed that P-cadherin accumulated at cell-cell contacts (Figure 1c ). Taken together these data indicate that P-cadherin expression is restricted to ARMS.
Furthermore expression of a dominant negative variant of PAX3 (Pax3-En) 16 in Rh4 and Rh5 ARMS cell lines, decreased P-cadherin expression level and impaired its accumulation at cell-cell contacts (Figures 1d and e) . These data suggest that P-cadherin transcription is regulated by PAX3.
P-cadherin lies genetically downstream of Pax3
As PAX3-FOXO1A oncogenic activity is likely due to reactivation of a developmental program downstream of Pax3, and as Pax3 is a key regulator of skeletal muscle development, 17 we examined the link between Pax3 and P-cadherin during early myogenesis. We first analyzed P-cadherin expression in mouse embryos from embryonic day (E) 10.5 to E12.5 by whole-mount in situ hybridization. P-cadherin transcripts were detected in somites ( Figure 2A , panels a-c, black arrows), the ectoderm of limb buds as described in 18 ( Figure 2A , panels a-c, white arrowheads), otic vesicle ( Figure 2A , panels a and b), branchial arches ( Figure 2A , panel a) and mammary glands at E12.5 ( Figure 2A , panel c, black arrowhead). We further characterized the somitic expression of P-cadherin by immunofluorescence on transverse sections of E10.5 Pax3 EGFP8/ þ mouse embryos. 19 Pax3 (green fluorescent protein (GFP)) was expressed in MPCslocated in the somitic epithelium of the dermomyotome ( Figure 2B , panel a, Dm) and in MPCs of the myotome ( Figure 2B , panel a, Myo), while differentiating myoblasts were labeled by Myogenin ( Figure 2B , panel b). P-cadherin was strongly expressed in the epaxial and central dermomyotome ( Figure 2B , panel b). Some P-cadherin positive cells co-localized with GFP (Pax3) in the myotome, but virtually none of the differentiating, Myogenin-positive cells co-expressed P-cadherin (Figure 2b , panels c and d, arrows). We conclude that P-cadherin is specifically expressed in MPCs during early myogenesis.
We next analyzed P-cadherin expression in different Pax3 genetic backgrounds at E11.5. P-cadherin expression in Pax3-En-ILZ/ þ (dominant negative Pax3-En) embryos, which display a hypomorphic phenotype when compared with Pax3 ILZ/ILZ embryos, 20 P-cadherin expression was markedly decreased in somites ( Figure 2C , panels g and h). We therefore conclude that expression of P-cadherin in somites is transcriptionally regulated by Pax3.
P-cadherin is a direct transcriptional target of PAX3-FOXO1A In order to determine whether P-cadherin is a direct PAX3/7-FOXO1A gene target, we investigated the presence of potential PAX3/7-binding sites in the P-cadherin promoter sequence. Specifically, a conserved 160-bp region at about À 2 kb upstream of the transcription start site, that was recently identified as a PAX3-FOXO1A-binding site in ARMS cells by genome-wide analysis, 21 contained three putative PAX3/7-binding sites (P1-P3) (Figure 3a) . Using luciferase reporter assay, we observed that this fragment of P-cadherin promoter (pP-cad-P1P2P3) was activated by PAX3-FOXO1A and PAX7-FOXO1A at levels comparable to those of a control promoter sequence containing five multimerized Pax3/7-binding sites (5xPax3/7; 5 ( Figure 3b ). Moreover, chromatin immunoprecipitation (ChIP) experiments in Rh4 cell line with an anti-PAX3/7 antibody that was previously used in ChIP assays to precipitate PAX3/7 and PAX3/7-FOXO1A 22 demonstrated that PAX3-FOXO1A and/or PAX3/7 bind specifically to the 160-bp sequence at À 2 kb from the P-cadherin transcription start site (P-cad À 2 kbp) ( Figure 3c ). Electrophoretic mobility gel shift assays revealed that PAX3-FOXO1A only bound to P2 (Figure 3d left panel, arrow). The specificity of this binding was confirmed by disruption of the P2/Flag-tagged PAX3-FOXO1A complex with an anti-Flag antibody or excess of non-biotinylated P2 probe, but not with an irrelevant antibody or excess of non-biotinylated P2 probe mutated in the PAX-binding site (Figure 3d right panel) . Luciferase reporter assays using the fragment of the P-cadherin promoter that harbors this mutation of the P2-binding site (pP-cad-P1P2*P3, Supplementary Table S1) revealed that the responsiveness of the P-cadherin promoter to Pax3/7-FOXO1A factors depends on the P2-binding site (Figure 3b ). These experiments show that P-cadherin is a new direct transcriptional target of PAX3-FOXO1A in ARMS. P-cadherin expression inhibits C2C12 myoblast differentiation To determine the role of P-cadherin in skeletal muscle cells, we generated stable C2C12 cell lines expressing non-tagged wildtype P-cadherin (C2C12 Pcad). As controls, parental and C2C12 myoblasts expressing the LZRS empty vector (C2C12 LZRS) were used. P-cadherin expression in the obtained clones was assessed by immunoblotting ( Figure 4A ) and clones 2, 8 and 9 were selected for further analysis. P-cadherin was recruited to cell-cell contact sites ( Figure 4B ) demonstrating the functionality of overexpressed P-cadherin. We then examined the capacity of myoblasts expressing P-cadherin to differentiate by replacing the growth medium with differentiation medium. A significant reduction in myotube formation and in the fusion index was observed in C2C12 Pcad myoblasts ( Figure 4C ). Moreover, P-cadherin expression affected the expression of Myogenin and Troponin T, two muscle-specific proteins ( Figure 4D ). These data show that P-cadherin expression inhibits myogenesis induction and myoblast fusion.
P-cadherin regulates cell transformation
To analyze the role of P-cadherin in cell proliferation and transformation, we first measured the proliferation rate in C2C12 LZRS and C2C12 Pcad myoblasts. Although in non-confluent cultures in growth medium the proliferation rate of C2C12 LZRS and C2C12 Pcad myoblasts was similar ( Figure 5A ), in confluent cultures the percentage of bromodeoxyuridine incorporation was slightly higher in C2C12 Pcad myoblasts than in C2C12 LZRS myoblasts. This difference was clearly significant in confluent cells that had been switched to differentiation medium for 1 day (D1). This finding demonstrates that P-cadherin expression bypasses Conversely, and as previously described, 23 it was markedly decreased in differentiating control C2C12 LZRS myoblasts. We then analyzed whether P-cadherin might induce myoblast transformation by performing soft agar assays. C2C12 Pcad myoblasts could form colonies in soft agar, whereas C2C12 LZRS myoblasts did not ( Figure 5C ).
We next analyzed the role of P-cadherin in the pathologic context of ARMS. We generated stable ARMS cell lines in which P-cadherin expression was inactivated by RNA interference (Pcad short interfering RNA (shRNA)). After selection, a reduction of 80% of P-cadherin protein expression level was observed in Rh4 cell line ( Figure 5D ). ARMS cell lines expressing a Luciferase shRNA (Luci shRNA) were used as controls. We then examined whether P-cadherin silencing affected foci formation. The number of foci was reduced in Rh4 Pcad shRNA cell line compared with parental and Rh4 Luci shRNA cell lines ( Figure 5E ). Similar results were obtained using a second P-cadherin shRNA (data not shown).
Unfortunately, we could not analyze the impact of P-cadherin knockdown on the transforming ability of the ARMS-derived cell lines Rh4 and Rh5 because these cell lines hardly form colonies in soft agar.
These results show that P-cadherin expression induces myoblast transformation and that inhibition of P-cadherin expression in the Rh4 ARMS cell line restores cell-cell contact growth inhibition, a hallmark of transformation.
P-cadherin promotes migration and invasion
We then investigated whether P-cadherin could modulate migration of C2C12 myoblasts and ARMS cell lines. By recording random cell movements or using the wound-healing migration assay, we observed that C2C12 Pcad myoblasts were significantly more mobile than the control C2C12 LZRS cells ( Figures 6A and C) . Conversely, Rh4 Pcad shRNA cell line moved slower than Rh4 Luci shRNA cell line ( Figures 6B and D) .
We then analyzed the effect of P-cadherin expression or silencing on cell invasion through Matrigel. P-cadherin expression enhanced invasiveness of C2C12 Pcad myoblasts through Matrigel ( Figure 6E ). Conversely, knockdown of P-cadherin decreased the ability of Rh5 cell line to invade Matrigel by around 50% in comparison with control Rh5 Luci shRNA cell line ( Figure 6F ). As the Rh4 ARMS cell line did not invade through Matrigel, we used a three-dimensional collagen spheroid outgrowth assay. 24 Spheroids formed by Rh4 Luci shRNA and Rh5 Luci shRNA cell lines contained cells that progressively infiltrated the surrounding collagen gel ( Figure 6G , panels a and c). Conversely, in spheroids formed by Rh4 Pcad shRNA and Rh5 Pcad shRNA cell lines, significantly fewer cells invaded the collagen gel ( Figure 6G , panels b and d). Similar results were obtained using a second P-cadherin shRNA (data not shown). These data demonstrate that P-cadherin is required for migration and invasion of ARMS cell lines.
P-cadherin-dependent cadherin switching
As cadherin switching is a hallmark of metastatic progression, 9, 10 we analyzed whether P-cadherin expression in C2C12 myoblasts affected the expression and/or localization of N-and M-cadherin, the two cadherins expressed in normal muscle and involved in its differentiation. The expression levels of N-and M-cadherin in C2C12 Pcad myoblasts were lower than in C2C12 LZRS myoblasts (Figure 7a ). Moreover, in C2C12 Pcad myoblasts, N-and Mcadherin did not accumulate any longer at cell-cell contacts (Figure 7b ). Conversely, in Rh4 Pcad shRNA cell line, the expression level of N-cadherin, but not of M-cadherin, was higher than in Rh4 Luci shRNA cell line (Figure 7c ) and both N-and M-cadherin resumed their localization at cell-cell contacts (Figure 7d ). Taken together these data indicate that N-and M-cadherin expression and localization are inversely correlated with P-cadherin expression.
DISCUSSION
PAX gene rearrangements are frequently associated with human diseases and cancers.
25 PAX3 and PAX7 are major regulators of skeletal muscle development, 17 and the chromosomal translocations generating the hybrid transcription factors PAX3-FOXO1A, PAX7-FOXO1A and PAX3-NCOA1 are implicated in ARMS oncogenesis. 2, 6 Here we demonstrate that P-cadherin is a direct PAX3-FOXO1A transcriptional target involved in the pathogenesis of ARMS. Moreover, the analysis of transcriptomic data sets of RMS samples revealed that P-cadherin mRNA expression was significantly higher in ARMS samples from patients with metastasis. As tumor invasion and metastasis are hallmarks of ARMS and the first cause of patient death, our study suggests that P-cadherin could be a biomarker of ARMS and a therapeutic target for ARMS treatments. This is consistent with the specific detection of P-cadherin mRNA and protein expression in ARMS from two independent cohorts of patients. 26, 27 The identification of PAX3/PAX7-FOXO1A targets is essential for understanding the molecular mechanisms leading to the aggressiveness of ARMS. It is generally accepted that PAX3-FOXO1A and PAX7-FOXO1A role in ARMS cell behavior is mainly the result of their deregulation of PAX3 or PAX7 specific targets, leading to reactivation of the developmental program of myogenic specification. Here we demonstrate by several approaches that P-cadherin is a direct PAX3-FOXO1A transcriptional target in ARMS cell lines. This was also recently suggested by a genome-wide analysis of the direct targets of PAX3-FOXO1A. 21 Moreover, our in vivo experiments show that P-cadherin is expressed in Pax3 positive MPCs during mouse embryogenesis and that P-cadherin lies downstream of PAX3-FOXO1A. Our data suggest that P-cadherin might also be a PAX7-FOXO1A gene target. This hypothesis could not be addressed in vivo as mice expressing PAX7-FOXO1A in the Pax7 locus are not available. Moreover, we observed that P-cadherin expression in Pax7 null embryos is not affected, a result that can be explained by Pax3 compensatory effects. 28 As P-cadherin expression is higher in metastatic ARMS, we analyzed its impact on characteristics of metastatic cells in vitro. We show that P-cadherin is involved in ARMS cell proliferation, transformation, migration and invasion. Thus in addition to pancreatic, gastric, colorectal and breast cancer, [29] [30] [31] P-cadherin contributes to the oncogenesis of ARMS.
A hallmark of metastatic progression is the dynamic regulation of cadherins. Cadherin isoform switching (cadherin switching) occurs during normal developmental processes to allow cell types to segregate. Tumor cells often recapitulate this activity, which results in an aggressive tumor cell type that gains the ability to leave the site of the tumor, migrate, invade and metastasize. 32 This cadherin switch is part of the epithelial-to-mesenchymal transition process. We observed that P-cadherin induces a cadherin switch, leading to the downregulation/mislocalization of N-and M-cadherins, the classical muscle cadherins. We previously reported such a switch in RMS cell lines. 11, 12 It will be now important to identify the mechanisms involved in the cadherin switch in RMS and to investigate whether signaling pathways, such as RhoGTPases, or transcription factors such as Snail, Twist and ZEB, which are involved in the classical switch of cadherins observed during epithelial-tomesenchymal transition, also have a role in the cadherin switch induced by P-cadherin. Interestingly, Snail1 is overexpressed in ARMS but not in ERMS, suggesting that Snail1 could have a role in the downregulation of N-and M-cadherins in ARMS. 33 Finally, P-cadherin function during myogenesis in vivo was unknown. Our data reveal that P-cadherin is expressed in MPCs located both in the dermomyotome and in primary myotome. The P-cadherin-positive MPCs in the myotome are not differentiated. Once they differentiate and start to express myogenic regulatory factors, P-cadherin expression is lost. During embryonic development, the dermomyotome undergoes epithelial-to-mesenchymal transition that triggers the invasion of the primary myotome by a MPC population, which maintains Pax3 and Pax7 expression. 34, 35 MPCs can either proliferate or terminally differentiate, and a balance between these two processes ensures the skeletal muscle growth. The nature of P-cadherin-expressing cells in vivo combined with the behavior of P-cadherin-expressing cells in vitro suggests that, during embryonic development, P-cadherin might be an epithelial-tomesenchymal transition inductor at the dermomyotome, thus facilitating the migration of cells to the myotome and/or that it might be involved in MPCs proliferation. Hence, P-cadherin expression in the pathological context of ARMS might favor both tumor formation and dissemination.
The impact of P-cadherin on tumor progression in different cancer cell types and now in ARMS aggressiveness suggests that P-cadherin may be a potential therapeutic target. The biochemical nature of this transmembrane receptor has already led to the design of a human monoclonal antibody that shows anti-tumor and anti-metastatic activities in xenografted mouse models of pancreatic, gastric, colorectal and breast cancers. 36, 37 As tumor invasion and metastasis is a hallmark of ARMS and the cause of patients' death, these promising results together with our work suggest that targeting P-cadherin with monoclonal antibodies might open the way for the development of new therapeutic strategies against aggressive ARMS.
MATERIALS AND METHODS

Microarrays analysis
The described HG-U133plus2.0 Affymetrix microarray data of RMS tumor samples 13 and three other data sets 3, 14, 15 were used. Boxplots represent the RNA normalized log2 intensity values of the probe sets corresponding to P-cadherin (probe set: 203256_at, HUGO gene symbol: CDH3) in the following sample groups: (1) ERMS and PAX3/7-FOXO1A fusion-negative samples (ARMSfn), (2) PAX3/7-FOXO1A fusion-positive samples (ARMSfp) and (3) PAX3-NCOA1 fusion-positive samples.
Cell lines
C2C12 mouse myoblasts were cultured as described. 38 Short interfering RNA constructs were made using the retroviral vector RNAi-ready pSIREN-RetroQ according to the manufacturer's protocol (Clontech, Saint-Germain-en-Laye, France). The oligonucleotides used to suppress endogenous P-cadherin expression are listed in Supplementary  Table S1 . Bold letters correspond to oligonucleotides (1759-1777) for the shRNA- 1 and (1921-1939) for the shRNA-2 of the human P-cadherin cDNA sequence (NM_001793.4). Retrovirus production in Phoenix cells and infection was performed as described. 39 Rh4 and Rh5 cell lines infected with P-cadherin shRNAs were selected in medium containing 0.5 mg/ml puromycin. As control, we used the Luciferase shRNA (Luci shRNA) described in Kucharczak et al.
12
Mice Generation and genotyping of Pax3
and Pax3 Pax3-En-IRES-nLacZ/ þ (abbreviated Pax3 Pax3-En-ILZ/ þ ) 20 mice were carried out as described as whole-mount in situ hybridization with digoxigenin-labeled probes 40 and X-gal staining. 20 The P-cadherin probe was provided by M Takeichi (Kyoto, Japan). Fluorescent immunohistochemistry analysis of mouse sections was carried out as described, 5 using home-made rabbit polyclonal anti-Pcadherin and monoclonal anti-Myogenin (DAKO, Trappes, France) antibodies. Primary antibodies were revealed with Cy5-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, Suffolk, UK) or Alexa Fluor 594-conjugated goat anti-rabbit IgG (Molecular Probes, Life Technologies, Saint Aubin, France, Interchim).
Plasmid constructs
The 455-bp P-cadherin promoter region that contains the putative PAX3/7-binding sites (pP-cad-P1P2P3) located between nt (nucleotide) À 1928 and nt À 1472 from the transcription start site was PCR-amplified using genomic DNA from human peripheral blood mononuclear cells. The P-cadherin promoter region containing the mutated P2 site (similar mutations as in the P2mut sequence used for the electrophoretic mobility shift assay experiments (Supplementary Table S1)) was synthetized by GenScript (pP-cad-P1P2*P3). The P34TKZ plasmid was used as template for amplification of five Pax3/7-multimerized-binding sites (p5XPax3/7). 5 The pP-cad-P1P2P3, pP-cadP1P2*P3 and p5Xpax3/7 fragments were inserted upstream the Luciferase gene in the pGL3-enhancer vector (pGL3-E-LUC, Promega, Charbonnieres, France). PAX3-FOXO1A and PAX7-FOXO1A were PCR amplified from the pFLDR-PAX3-FKHR and pBluescript PAX7-FKHR plasmids, respectively and inserted in frame with the Flag-tag into the pBRIT retroviral vector. 42 pMSCV-IRES-eGFP empty vector and pMSCVPax3-En-IRES-eGFP were described. 16 All the constructs were checked by DNA sequencing.
Quantitative real-time RT-PCR Total RNAs from cell lines were prepared as described. 39 Primers used are described in Supplementary Table S1 . Human TBP mRNA was used as reference. The control condition was set to 1 and expression levels are presented as bar-graphs of the mean values ± s.e.m.
Luciferase reporter assay
Transfections were performed with TransIT-LT1 (Mirus, Madison, WI, USA) in six-well plates following the manufacturer's instructions. Cells were cotransfected with the indicated pGL3-E-LUC reporter plasmids, the Renilla luciferase expression vector as an internal control for normalization (pRL-TK plasmid, Promega) and the pBRIT plasmids. After 24 h, cells were harvested and assayed for luciferase activity (Dual-Luciferase Reporter Assay System, Promega).
Electrophoretic mobility shift assays
Protein extracts containing the PAX3-FOXO1A-Flag protein were prepared from HEK293T cells transfected with pBRIT-PAX3-FOXO1A-Flag using JetPei (PolyPlus-Transfection). Nuclear extracts were obtained using the NEPERNuclear and Cytoplasmic extraction reagents (Thermo Fisher Scientific, Waltham, MA, USA) following the instructions. The 5 0 -biotin-conjugated oligonucleotides and unlabeled probes used are described in Supplementary Table S1 . Biotin-labeled double-stranded DNA was mixed with nuclear proteins cell extracts. Gel mobility shift assays and hybridization were performed using the LightShift Chemiluminescent EMSA kit (Thermo Fisher Scientific) according to instructions.
Chromatin immunoprecipitation assay
Protein-DNA complexes were crosslinked with 1% formaldehyde, enzymatically sheared and immunoprecipitated with the anti-Pax3/7 (N-19) antibody (Santa Cruz, Santa Cruz, CA, USA) according to the ChIP kit manufacturer's protocol (Active Motif, La Hulpe, Belgium). DNA was recovered using PCR purification columns (Macherey-Nagel, Dü ren, Germany). Immunoprecipitated DNA was analyzed by qPCR using the Roche LightCycler 480 real-time PCR system. Data were normalized with inputs taken from samples before immunoprecipitation and amplified in the same way. Primers are listed in Supplementary Table S1 .
Proliferation assay
Cells were seeded at different stages of confluency. For the D1 condition, 100% confluent cells were shifted to differentiation medium for 24 h. Bromodeoxyuridine was added to the medium for 4 h; then cells were fixed, incubated with the anti-bromodeoxyuridine antibody (BD Biosciences, Pont de Claix, France) and stained with the Hoechst dye as described. 12 Foci formation was monitored by phase-contrast microscopy.
Soft agar assay
Thirty-five-millimeter-sized dishes were coated with 2 ml of 0.6% agarose in DMEM/HAM-F12 containing 10% FCS. C2C12 LZRS and C2C12 Pcad myoblasts were resuspended at 2.5 Â 10 4 cells in 1.5 ml DMEM/HAM-F12 supplemented with 10% FCS containing 0.3% agarose and then layered on the pre-coated 35 mM dishes. The agar was allowed to solidify at room temperature for 25 min before adding 2 ml of growth medium. Every 2 days, 1 ml of growth medium was added. After 2 weeks, the colonies were counted and phase-contrast images were acquired.
Time lapse imaging
Cells were imaged using an Axiovert inverted microscope (Carl Zeiss, Le Pecq, France) equipped with motorized stage, heated and CO 2 -regulated incubator. Phase-contrast images were taken every 20-30 min overnight using a Â 10/0.3 NA PH1 DIC1 objective and captured with a CCD MicroMax 1300 Y/HS camera (Roper Scientific, Evry, France) controlled by the Metamorph 7.0 software. The migration speeds were calculated by tracking the nucleus of individual cells using the tracking module of Metamorph.
Wound-healing assay
Monolayers of confluent cells were scratched using a pipette tip and fresh culture medium was added. Wound closure was monitored by collecting phase-contrast images every 20-30 min starting after wounding and until complete closure. Images were recorded by time lapse imaging and analyzed using the Image-J software to measure the width of the scratch at various time points. The last width value was subtracted from the initial width to obtain the 'Covered Area'. All covered areas were then normalized to control condition.
Gel electrophoresis and immunoblotting
Protein extracts prepared as described in Bach et al. 38 were resolved on polyacrylamide gels and transferred to Immobilon-P membranes. Membranes were then incubated with a mouse monoclonal antibody against P-cadherin (32-4000, Invitrogen, Saint Aubin, France) or a homemade rabbit polyclonal antibody raised against the extracellular domain (aa184 to aa519) of human P-cadherin, anti-Troponin T (T6277, SigmaAldrich, St Louis, MO, USA), anti-N-cadherin (C70320, Transduction Laboratories, Pont de Claix, France), anti-M-cadherin (NanoTools, Munich, Germany), and anti-a-Tubulin or anti-b-Actin (A2066, Sigma-Aldrich) antibodies. Membranes were processed as described. 43 For protein quantification, the Odyssey system from LI-COR Biosciences (Cambridge, UK) was used.
FACS sorting
Rh4 and Rh5 cell lines seeded on 10-cm diameter plates were transfected with pMSCV-IRES-eGFP or pMSCV-Pax3-En-IRES-eGFP using TransIT-LT1 (Mirus). Forty-eight hours after transfection, cells were harvested and sorted by fluorescence activated cell sorting (FACS) based on the GFP expression (FacsAria).
Immunohistochemistry Cells were prepared as described. 38 Myogenin and Troponin T expression was detected as described. 44 Mouse (32-4000, Invitrogen) or home-made rabbit anti-P-cadherin and anti-M-cadherin, and mouse anti-N-cadherin (C70320, Transduction Laboratories) antibodies were used. Primary antibodies were revealed with Alexa Fluor 488 or 546-conjugated goat anti-mouse or anti-rabbit IgG (Molecular Probes, Interchim).
Transwell invasion assays
Transwell invasion assays were performed as described in Gadea et al. 45 Spheroid invasion assays Cells were processed as described 24 except that the plate coating is similar to the matrix that surrounds cells.
